{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T23:10:58Z","timestamp":1776726658704,"version":"3.51.2"},"reference-count":19,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:00:00Z","timestamp":1714694400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:00:00Z","timestamp":1714694400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Uncertainty surrounds the optimal routine laboratory monitoring in acne patients treated with isotretinoin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Our aim was to evaluate the risk of mild and severe laboratory abnormalities in patients with acne starting isotretinoin versus oral antibiotic treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A global population\u2010based retrospective cohort study assigned two groups of patients with acne\u2010prescribed isotretinoin (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200979,012) and oral antibiotics (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200979,012). Comprehensive propensity\u2010score matching was conducted.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Compared to acne patients treated with oral antibiotics, those under isotretinoin demonstrated an increased risk of grade \u22653 hypertriglyceridemia (hazard ratio [HR], 7.85; 95% confidence interval [CI], 5.58\u201311.05;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001) and grade \u22653 elevated aspartate transaminase (AST) levels (HR, 1.45; 95% CI, 1.13\u20131.85;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.003) within the initial 3\u2009months of treatment. The absolute risk of these abnormalities among isotretinoin initiators was 0.4% and 0.2%, respectively. The risk difference of these findings was clinically marginal: 3 and 1 additional cases per 1,000 patients starting isotretinoin, respectively. There was no significant risk of grade \u22653 impairment in cholesterol, alanine transaminase, gamma\u2010glutamyl transferase, or creatinine levels under isotretinoin. Most laboratory abnormalities were documented 1\u20133\u2009months after drug initiation in time\u2010stratified analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Isotretinoin is associated with a clinically marginal increased risk of severe hypertriglyceridemia and hypertransaminasemia. Routine blood testing should be performed 1\u20133\u2009months after commencing therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ijd.17225","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T23:44:40Z","timestamp":1714779880000},"page":"1740-1747","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Risk and timing of isotretinoin\u2010related laboratory disturbances: a population\u2010based study"],"prefix":"10.1111","volume":"63","author":[{"given":"Shirin","family":"Emtenani","sequence":"first","affiliation":[{"name":"L\u00fcbeck Institute of Experimental Dermatology University of L\u00fcbeck  L\u00fcbeck Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7643-0061","authenticated-orcid":false,"given":"Mariam","family":"Abdelghaffar","sequence":"additional","affiliation":[{"name":"School of Medicine, Royal College of Surgeons in Ireland  Manama Bahrain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf J.","family":"Ludwig","sequence":"additional","affiliation":[{"name":"L\u00fcbeck Institute of Experimental Dermatology University of L\u00fcbeck  L\u00fcbeck Germany"},{"name":"Department of Dermatology University Hospital of Schleswig Holstein (UKSH), Campus L\u00fcbeck  L\u00fcbeck Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enno","family":"Schmidt","sequence":"additional","affiliation":[{"name":"L\u00fcbeck Institute of Experimental Dermatology University of L\u00fcbeck  L\u00fcbeck Germany"},{"name":"Department of Dermatology University Hospital of Schleswig Holstein (UKSH), Campus L\u00fcbeck  L\u00fcbeck Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9971-9151","authenticated-orcid":false,"given":"Khalaf","family":"Kridin","sequence":"additional","affiliation":[{"name":"L\u00fcbeck Institute of Experimental Dermatology University of L\u00fcbeck  L\u00fcbeck Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,5,3]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610\u20100387.2007.06274.x"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12149"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257\u2010020\u201000560\u2010w"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.09.055"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.4161\/derm.1.3.9364"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.12.037"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15207"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102133.1993.tb03336.x"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1159\/000057887"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.3091"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.142.8.1016"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.03.019"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.618"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/SIM.6004"},{"key":"e_1_2_6_16_1","unstructured":"Cancer Institute N.Common terminology criteria for adverse events (CTCAE) common terminology criteria for adverse events (CTCAE) v5.0.2017. Accessed September 17 2023.https:\/\/www.meddra.org\/"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.JAAD.2019.06.025"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0365\u201005962012000300005"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003\u20104819\u2010107\u20101\u201063"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/095466301750163509"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.17225","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ijd.17225","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.17225","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:23:49Z","timestamp":1773015829000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijd.17225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,3]]},"references-count":19,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1111\/ijd.17225"],"URL":"https:\/\/doi.org\/10.1111\/ijd.17225","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,3]]},"assertion":[{"value":"2024-03-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}